# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k071811   
B. Purpose for Submission: New Device   
C. Measurand: Ethyl Alcohol (Ethanol)   
D. Type of Test: Quantitative   
E. Applicant: Dade Behring, Inc.   
F. Proprietary and Established Name Dimension $\textsuperscript { \textregistered }$ Ethyl Alcohol (ETOH)   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DIC</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR§ 862.3040</td><td rowspan=1 colspan=1>91-Toxicology</td></tr></table>

# H. Intended Use:

1. Intended use(s): See Indications for use below

2. Indication(s) for use:

The ETOH method is an in-vitro diagnostic test for the quantitative measurement of ethyl alcohol in human serum, plasma and urine. Ethyl alcohol test results may be used in the diagnosis and treatment of alcohol intoxication and poisoning.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Dimension $\textsuperscript { \textregistered }$ Clinical Chemistry System

# I. Device Description:

The Dimension $\textsuperscript { \textregistered }$ ETOH Flex $\textsuperscript { \textregistered }$ reagent cartridge is prepackaged in-vitro diagnostic test method that is specifically designed to be used on the Dade Behring Dimension $\textsuperscript { \textregistered }$ Clinical Chemistry System. The reagents contained in the Dimension $\textsuperscript { \textregistered }$ ETOH Flex $\textsuperscript { \textregistered }$ reagent cartridge are: Reagent 1 which contains the buffering system and; Reagent 2 which contains alcohol dehydrogenase (ADH), the coenzyme nicotinamide adenine dinucleotide (NAD), buffer, preservatives and stabilizers.

J. Substantial Equivalence Information:   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Dimension®ETOH Flex®reagentcartridge</td><td colspan="1" rowspan="1">Dimension® ALCFlex reagentCartridge(k904302)</td><td colspan="1" rowspan="1">Syva® Emit® IIPlusEthyl AlcoholAssay(k010960)</td></tr><tr><td colspan="1" rowspan="1">Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The Dimension®ETOH Flex® reagentcartridge is an in-vitro diagnostic testfor the quantitativemeasurement of ethylalcohol (ethanol) inhuman serum,plasma, and urine.Ethyl alcohol testresults may be usedin the diagnosis andtreatment ofalcohol intoxicationand poisoning.</td><td colspan="1" rowspan="1">The ALC method used inthe Dimension® clinicalchemistry system is an invitro diagnostic testintended to measure ethylalcohol in human serumand supernatants fromprecipitated whole bloodand to qualitativelydetect ethyl alcohol inurine. Ethyl alcohol testresults may be used inthe diagnosis andtreatment ofalcohol intoxication andpoisoning.</td><td colspan="1" rowspan="1">The EMIT® II PlusEthyl Alcohol Assayis intended for use inthe quantitativeanalysis of ethylalcohol (ethanol) inhuman urine, serum,or plasma.</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Dimension®ETOH Flex®reagentcartridge</td><td colspan="1" rowspan="1">Dimension® ALCFlex® reagentCartridge(k904302)</td><td colspan="1" rowspan="1">Syva® Emit® IIPlusEthyl AlcoholAssay(k010960)</td></tr><tr><td colspan="1" rowspan="1">Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Plasma, serum, andurine.</td><td colspan="1" rowspan="1">Serum, supernatants fromprecipitated whole bloodand urine.</td><td colspan="1" rowspan="1">Plasma, serum, andurine.</td></tr><tr><td colspan="1" rowspan="1">Principle</td><td colspan="1" rowspan="1">The ETOH method isbased on anenzymaticreaction.</td><td colspan="1" rowspan="1">The ethyl alcohol (ALC)method is a modificationof the alcoholdehydrogenase (ADH)enzymatic procedure.</td><td colspan="1" rowspan="1">The Emit®II PlusEthyl Alcohol Assayis based on anenzymatic reaction.</td></tr><tr><td colspan="1" rowspan="1">Measurement</td><td colspan="1" rowspan="1">Bichromatic Rate</td><td colspan="1" rowspan="1">Bichromatic Rate</td><td colspan="1" rowspan="1">Bichromatic Rate</td></tr><tr><td colspan="1" rowspan="1">Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">MeasuringRange</td><td colspan="1" rowspan="1">3 - 300 mg/dL</td><td colspan="1" rowspan="1">0 - 300 mg/dL</td><td colspan="1" rowspan="1">10 - 600 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">4 uL</td><td colspan="1" rowspan="1">3 uL</td><td colspan="1" rowspan="1">4 uL</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

<table><tr><td rowspan=1 colspan=1>STANDARDS</td></tr><tr><td rowspan=1 colspan=1>Title and Reference Number</td></tr><tr><td rowspan=1 colspan=1>BSI BS EN 13640 :Stability Testing of In Vitro Diagnostic Reagents</td></tr><tr><td rowspan=1 colspan=1>CLSI: Interference Testing in Clinical Chemistry; Approved Guideline (EP 7-A)</td></tr><tr><td rowspan=1 colspan=1>CLSI: Method Comparison and Bias Estimation Using Patient Samples; ApprovedGuideline (EP09-A2)</td></tr><tr><td rowspan=1 colspan=1>CLSI: Evaluation of Precision Performance of Clinical Chemistry Devices;Approved Guideline (EP5-A)</td></tr></table>

<table><tr><td rowspan=1 colspan=4>Other Standards</td></tr><tr><td rowspan=1 colspan=4>GUIDANCE</td></tr><tr><td rowspan=1 colspan=1>Document Title</td><td rowspan=1 colspan=1>Office</td><td rowspan=1 colspan=1>Office Division</td><td rowspan=1 colspan=1>Web Page</td></tr><tr><td rowspan=2 colspan=1>Format for Traditional andAbbreviated 510(k)s -Guidance for Industry andFDA Staff</td><td rowspan=2 colspan=1>OIVD</td><td rowspan=2 colspan=1>−</td><td rowspan=1 colspan=1>http://www.fda.gov/cdrh/ode/guidance/1567.html</td></tr><tr><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>In Vitro Diagnostic Devices:Guidance for thePreparation of 510(k)Submissions</td><td rowspan=2 colspan=1>OCER</td><td rowspan=2 colspan=1>−</td><td rowspan=1 colspan=1>http://www.fda.gov/cdrh/manual/ivdmanul.html</td></tr><tr><td rowspan=1 colspan=1></td></tr></table>

# L. Test Principle:

The Ethyl Alcohol Assay is based on an enzymatic reaction. Reagent 1 contains the buffering system. Reagent 2 contains alcohol dehydrogenase (ADH), the coenzyme nicotinamide adenine dinucleotide (NAD), buffer, preservatives, and stabilizers. The ADH catalyzes the oxidation of ethyl alcohol to acetaldehyde. During this reaction, NAD is reduced to NADH. The absorbance due to NADH (proportional to the ETOH concentration) is determined using a two-filter (340- $3 8 3 \mathrm { n m }$ ) bichromatic rate technique.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision studies were conducted by testing three levels of a commercially available control, serum pool, plasma pool and a urine pool. The samples were run in duplicate, twice a day for twenty days using one lot and one instrument. The results are presented in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>LowControl</td><td rowspan=1 colspan=2>MediumControl</td><td rowspan=1 colspan=2>HighControl</td><td rowspan=1 colspan=2>Serum Pool</td><td rowspan=1 colspan=2>Plasma Pool</td><td rowspan=1 colspan=2>Urine Pool</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD−</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>38.99</td><td rowspan=1 colspan=2>98.30</td><td rowspan=1 colspan=2>254.92</td><td rowspan=1 colspan=2>102.15</td><td rowspan=1 colspan=2>245.88</td><td rowspan=1 colspan=2>101.22</td></tr><tr><td rowspan=1 colspan=1>Withinrun</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>1.49</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>1.16</td><td rowspan=1 colspan=1>1.43</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.87</td></tr><tr><td rowspan=1 colspan=1>Withinlab</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>2.57</td><td rowspan=1 colspan=1>2.41</td><td rowspan=1 colspan=1>2.45</td><td rowspan=1 colspan=1>5.37</td><td rowspan=1 colspan=1>2.11</td><td rowspan=1 colspan=1>1.38</td><td rowspan=1 colspan=1>1.35</td><td rowspan=1 colspan=1>2.96</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>2.28</td><td rowspan=1 colspan=1>2.25</td></tr></table>

# b. Linearity/assay reportable range:

Linearity samples for plasma, serum and urine were prepared from two pools of each sample type with ethanol concentrations near the extremes of the assay range (low pool $0 \mathrm { m g / d L }$ and high pool $3 4 5 \mathrm { m g / d L }$ . The two pools were mixed to create 7 additional pools of intermediate concentrations. Five determinations of each pool were tested and a linear regression analysis was performed by the method of least squares. The instrument generates a flag which states “Above Assay Range” or "Below Assay Range". In addition to this, automatic dilutions are performed by the instrument for results that fall outside the assay range. Automatic dilutions are defined in the method parameters and cannot be changed by an operator.

The data provided in the table below and the detection limit (M.1.d. below) support the claimed measuring range of $3 - 3 0 0 \mathrm { m g / d L }$ :

o   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Serum</td><td rowspan=1 colspan=2>Plasma</td><td rowspan=1 colspan=2>Urine</td></tr><tr><td rowspan=1 colspan=1>3Sample</td><td rowspan=1 colspan=1>Theor.ETOHmg/dL</td><td rowspan=1 colspan=1>ObservedETOHmg/dL</td><td rowspan=1 colspan=1>Theor.ETOHmg/dL</td><td rowspan=1 colspan=1>ObservedETOHmg/dL</td><td rowspan=1 colspan=1>Theor.ETOHmg/dL</td><td rowspan=1 colspan=1>ObservedETOHmg/dL</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>-0.6</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>-0.8</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>62.8</td><td rowspan=1 colspan=1>62.3</td><td rowspan=1 colspan=1>65.7</td><td rowspan=1 colspan=1>68.8</td><td rowspan=1 colspan=1>66.7</td><td rowspan=1 colspan=1>68.3</td></tr><tr><td rowspan=1 colspan=1>m      3</td><td rowspan=1 colspan=1>94.1</td><td rowspan=1 colspan=1>94.1</td><td rowspan=1 colspan=1>98.6</td><td rowspan=1 colspan=1>102.9</td><td rowspan=1 colspan=1>100.1</td><td rowspan=1 colspan=1>98.7</td></tr><tr><td rowspan=1 colspan=1>       4</td><td rowspan=1 colspan=1>125.5</td><td rowspan=1 colspan=1>127.4</td><td rowspan=1 colspan=1>131.5</td><td rowspan=1 colspan=1>137.1</td><td rowspan=1 colspan=1>133.5</td><td rowspan=1 colspan=1>130.6</td></tr><tr><td rowspan=1 colspan=1>5d</td><td rowspan=1 colspan=1>156.9</td><td rowspan=1 colspan=1>159.3</td><td rowspan=1 colspan=1>164.4</td><td rowspan=1 colspan=1>167.6</td><td rowspan=1 colspan=1>166.8</td><td rowspan=1 colspan=1>162.5</td></tr><tr><td rowspan=1 colspan=1>I        6</td><td rowspan=1 colspan=1>188.3</td><td rowspan=1 colspan=1>193.1</td><td rowspan=1 colspan=1>197.2</td><td rowspan=1 colspan=1>200.3</td><td rowspan=1 colspan=1>200.2</td><td rowspan=1 colspan=1>195.1</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>219.7</td><td rowspan=1 colspan=1>223.1</td><td rowspan=1 colspan=1>230.1</td><td rowspan=1 colspan=1>231.8</td><td rowspan=1 colspan=1>233.6</td><td rowspan=1 colspan=1>228.1</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>251.1</td><td rowspan=1 colspan=1>256.1</td><td rowspan=1 colspan=1>263.0</td><td rowspan=1 colspan=1>250.7</td><td rowspan=1 colspan=1>266.9</td><td rowspan=1 colspan=1>256.0</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>313.8</td><td rowspan=1 colspan=1>313.8</td><td rowspan=1 colspan=1>328.7</td><td rowspan=1 colspan=1>328.7</td><td rowspan=1 colspan=1>333.7</td><td rowspan=1 colspan=1>333.7</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1.0121</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>0.9806</td><td rowspan=1 colspan=2>0.9794</td></tr><tr><td rowspan=1 colspan=1>intercept</td><td rowspan=1 colspan=2>-0.0725</td><td rowspan=1 colspan=2>4.0756</td><td rowspan=1 colspan=2>0.3799</td></tr><tr><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=2>0.999</td><td rowspan=1 colspan=2>0.999</td><td rowspan=1 colspan=2>0.999</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

This device does not include calibrators. The sponsor recommends using calibrators by Dade Behring Inc. ALC Calibrator, Catalog Number DC37A cleared k904308.

# d. Detection limit:

The detection limit represents the lowest concentration of analyte that can be detected with at least $9 5 \%$ probability. CLSI EP17-A was followed using 60 replicate determinations at two concentration levels to determine Limit of the Blank (LoB) and Limit of Detection (LoD). The LoD is $3 \mathrm { m g / d L }$ .

# e. Analytical specificity:

The Dimension ETOH assay was evaluated for interference according to CLSI EP7- A2. The following substances demonstrated no significant bias (defined as $< 1 0 \%$ ).

<table><tr><td rowspan=1 colspan=1>SubstanceTested</td><td rowspan=1 colspan=1>Substanceconcentration</td><td rowspan=1 colspan=1>EthylAlcoholmg/dL</td><td rowspan=1 colspan=1>Bias %</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin(hemolysate)</td><td rowspan=1 colspan=1>1000 mg/dL/Hemoglobin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>&lt;10</td></tr><tr><td rowspan=1 colspan=1>Bilirubin(unconjugated)</td><td rowspan=1 colspan=1>80 mg/dL</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>&lt;10</td></tr><tr><td rowspan=1 colspan=1>Bilirubin(conjugated)</td><td rowspan=1 colspan=1>80 mg/dL</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>&lt;10</td></tr><tr><td rowspan=1 colspan=1>Lipemia(Intralipid)</td><td rowspan=1 colspan=1>3000 mg/dL</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>&lt;10</td></tr></table>

An extensive list of other compounds was evaluated for interference and found to have no significant interference or cross reactivity. A list of these compounds is present in the product labeling.

f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device:

A split sample method comparison between the Dimension ETOH and Dimension ALC (serum) and Emit II Plus (urine). The assays were performed following CLSI EP9-A2. The correlations are as follows:

<table><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>Device range(mg/dL)</td><td rowspan=1 colspan=1>Predicaterange(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>-0.18</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>4.8- 277.0</td><td rowspan=1 colspan=1>5.0-273.0</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>136</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>8.8 - 293.7</td><td rowspan=1 colspan=1>9.1- 290.2</td></tr></table>

# b. Matrix comparison:

A serum / plasma comparison test was performed for the Dimension $\textsuperscript { \textregistered }$ ETOH Flex $\textsuperscript { \textregistered }$ assay. Forty samples ranging from 19.9 to $4 0 4 . 6 \mathrm { m g / d L }$ were compared and yielded the following linear regression line. $\mathbf { y } = 1 . 0 1 \mathbf { x } - 0 . 2 8$ with a correlation constant of 0.998.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
$b$ . Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

The sponsor’s expected value was established through literature. The pharmacological response to blood alcohol levels may vary from individual to individual. The fatal concentration has been reported to be greater than $4 0 0 \mathrm { m g / d L }$ [86.8 mmol/L].

(Sunshine I., Methodology for Analytical Toxicology, CRC Press, Inc, Cleveland,   
OH, 1975 pp 152-153.)   
Tietz NW, ed. Textbook of Clinical Chemistry. Philadelphia, PA: Elsevier  
Saunders Co; 2006:1300-1301

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.